Our study results are in accordance with their results, with shorter latency time in patients with anti-CTLA-4/PD-1 therapy, higher prevalence of headache in anti-CTLA-4/PD-1-induced hypophysitis, and more frequent TSH deficiency and LH/FSH deficiency in anti-CTLA-4/PD-1 induced hypophysitis compared to anti-PD-(L)1 monotherapy induced hypophysitis. Here, PLOD1 is linked to central congenital hypothyroidism.